Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan + ART in Acute HIV Infection
NCT02170246Phase 1Completed
- Sponsor
- Yale University
- Start
- Jan 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Yale University. Primary endpoint: Change in level of neopterin in the cerebrospinal fluid (CSF) at 48 weeks. Started Jan 2015; status: completed.
02
Drugs
telmisartan
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02170246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02170246.